ProfessorAnneLingford-Hughes

Hayes A, McGonigle J, Elliott R, Ersche K, Flechais R, Orban C, Murphy A, Smith D, Suckling J, Taylor E, Deakin JF, Robbins T, Nutt D, Lingford-Hughes A, Paterson Let al., 2022, The Relationship Between Reward and Impulsivity in Substance Dependence: An fMRI Study, Publisher: ELSEVIER SCIENCE INC, Pages: S103-S103, ISSN: 0006-3223

• Author Web Link
• Cite
• Citations: 1

Sparasci O, Bhui K, Biswas A, Chamberlain S, Dubicka B, Dudas R, Farooq S, Ford T, Husain N, Jones I, Killaspy H, Lee W, Lingford-Hughes A, Mulholland C, Rubinsztein J, Shankar R, Sharma A, Sinclair L, Stone J, Young Aet al., 2022, Impact of COVID-19 on mental health research: is this the breaking point?, BRITISH JOURNAL OF PSYCHIATRY, Vol: 220, Pages: 254-256, ISSN: 0007-1250

• Author Web Link
• Cite
• Citations: 4

Ostinelli EG, Smith K, Zangani C, Ostacher MJ, Lingford-Hughes AR, Hong JSW, Macdonald O, Cipriani Aet al., 2022, COVID-19 and substance use disorders: a review of international guidelines for frontline healthcare workers of addiction services, BMC PSYCHIATRY, Vol: 22

• Author Web Link
• Cite
• Citations: 2

Mozgunov P, Cro S, Lingford-Hughes A, Paterson LM, Jaki Tet al., 2022, A dose-finding design for dual-agent trials with patient-specific doses for one agent with application to an opiate detoxification trial, Pharmaceutical Statistics: the journal of applied statistics in the pharmaceutical industry, Vol: 21, Pages: 476-495, ISSN: 1539-1604

There is a growing interest in early phase dose-finding clinical trials studying combinations of several treatments. While the majority of dose finding designs for such setting were proposed for oncology trials, the corresponding designs are also essential in other therapeutic areas. Furthermore, there is increased recognition of recommending the patient-specific doses/combinations, rather than a single target one that would be recommended to all patients in later phases regardless of their characteristics. In this paper, we propose a dose-finding design for a dual-agent combination trial motivated by an opiate detoxification trial. The distinguishing feature of the trial is that the (continuous) dose of one compound is defined externally by the clinicians and is individual for every patient. The objective of the trial is to define the dosing function that for each patient would recommend the optimal dosage of the second compound. Via a simulation study, we have found that the proposed design results in high accuracy of individual dose recommendation and is robust to the model misspecification and assumptions on the distribution of externally defined doses.

• Abstract
• Publisher Web Link
• Author Web Link
• Open Access Link
• Cite

Grabski M, McAndrew A, Lawn W, Marsh B, Raymen L, Stevens T, Hardy L, Warren F, Bloomfield M, Borissova A, Maschauer E, Broomby R, Price R, Coathup R, Gilhooly D, Palmer E, Gordon-Williams R, Hill R, Harris J, Mollaahmetoglu OM, Curran HV, Brandner B, Lingford-Hughes A, Morgan CJAet al., 2022, Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder, AMERICAN JOURNAL OF PSYCHIATRY, Vol: 179, Pages: 152-162, ISSN: 0002-953X

• Author Web Link
• Cite
• Citations: 33